Atlas Trials

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Clinical trial NCT04505813 · SUSPENDED

Trial details

NCT number
NCT04505813
Sponsor
NexImmune Inc.
Status
SUSPENDED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed Refractory Multiple Myeloma
Start date
2020-08-17
Primary completion
2024-11-30
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.